Cargando…
Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience
Renal cell carcinoma is the 10th most common type of cancer, accounting for 3.7% of all cancers. Our study examines patients with metastatic renal cell carcinoma who received Axitinib or Nivolumab as second-line treatment. This study was designed as a retrospective analysis. Patients who received Ax...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578706/ https://www.ncbi.nlm.nih.gov/pubmed/37832108 http://dx.doi.org/10.1097/MD.0000000000035245 |